UBS’s Core Laboratories CLB Stock Holding History

UBS’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$15K	Hold	100	–	–	﹤0.01%	8343
2014 Q2	$17K	Sell	100 -200	-67%	-$35.6K	﹤0.01%	8255
2014 Q1	$60K	Sell	300 -200	-40%	-$37.8K	﹤0.01%	6597
2013 Q4	$95K	Buy	+500	New	+$93.1K	﹤0.01%	6125
2013 Q3	–	Sell	-9,600	Closed	-$1.46M	–	10380
2013 Q2	$1.46M	Buy	+9,600	New	+$1.36M	﹤0.01%	2900

Other funds holding CLB

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

VAM

Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

WHV Investments San Francisco, California $187M AUM 14.29% 1-Year Est. Return

UBS's CLB Position: Q3 2014 in Review

UBS increased its Core Laboratories (CLB) stake by 43% in Q3 2014, buying an estimated $3.6M and bringing the position to 78,026 shares worth $11.4M. The position accounts for 0.01% of the portfolio, ranked #1347.

UBS first reported a position in CLB in Q2 2013 and has held it in 6 quarters since. 344 funds tracked by Wall St. Rank hold CLB as of Q3 2014.

UBS held 78,026 shares of Core Laboratories worth $11.4M as of Q3 2014.
UBS bought 23,312 Core Laboratories shares in Q3 2014, an estimated $3.6M.
Core Laboratories made up 0.01% of UBS's portfolio in Q3 2014, its #1347 holding.
UBS first reported a position in Core Laboratories in Q2 2013 and has held it in 6 quarters since.
344 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.